DRUG
MECHANISM
USE
ADVERSE · NOTES
Somatostatin analogs (↓ GH, insulin, glucagon, gut hormones, splanchnic flow)
Acromegaly, carcinoid syndrome, VIPoma, esophageal varices
Cholesterol gallstones, steatorrhea, hypoglycemia/hyperglycemia
GH receptor antagonist (↓ IGF-1)
Acromegaly refractory to surgery/octreotide
↑ LFTs
Recombinant GH
GH deficiency, Turner, Prader-Willi, CKD short stature
SCFE, pseudotumor cerebri, hyperglycemia
V2 agonist
Central DI, nocturnal enuresis, hemophilia A, type 1 vWD
Hyponatremia, seizures
V1 (vasoconstriction) + V2
Septic shock (add-on), variceal bleeding
Ischemia
Uterine contraction, milk let-down
Labor induction/augmentation, postpartum hemorrhage
Uterine hyperstimulation, hyponatremia (ADH-like)
Cabergoline · bromocriptine
D2 agonists → ↓ prolactin
Prolactinoma, acromegaly adjunct, Parkinson (bromocriptine)
Nausea, orthostasis; cabergoline valvulopathy (high dose)
Leuprolide · goserelin (continuous)
GnRH agonists → downregulate pituitary receptors
Prostate cancer, breast cancer, endometriosis, fibroids, precocious puberty
Initial flare (add flutamide), hot flashes, bone loss
Degarelix · elagolix · relugolix
GnRH antagonists — no flare
Prostate cancer, endometriosis
Hot flashes
Pyrophosphate analogs → osteoclast inhibition
Osteoporosis, Paget disease, hypercalcemia of malignancy, bone metastases
Pill esophagitis, jaw osteonecrosis, atypical femur fractures, hypocalcemia
Monoclonal antibody to RANKL
Osteoporosis, bone metastases
Hypocalcemia, jaw osteonecrosis, rebound fractures after stopping
Teriparatide · abaloparatide
Intermittent PTH/PTHrP analog → ↑ osteoblast activity
Severe osteoporosis
Osteosarcoma (animal), transient hypercalcemia; avoid in Paget, prior radiation
Anti-sclerostin → ↑ formation, ↓ resorption
Severe osteoporosis
MI and stroke risk
↓ Osteoclast activity
Acute hypercalcemia (rapid, tachyphylaxis), Paget
Short-lived effect